Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine transdermal patch for mild cognitive impairment with Lewy bodies
ISRCTN17719546Phase 4Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivastigmine in mild cognitive impairment with Lewy bodies (MCI-LB), sponsored by The Chinese University of Hong Kong. Started Mar 2024; status: completed.
02
Drugs
rivastigmine
03
Conditions
mild cognitive impairment with Lewy bodies (MCI-LB)
Beyond the preview
Go deeper on ISRCTN17719546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17719546.